Zim Laboratories Ltd. AI Stock Analysis
Want to see IN:ZIMLAB full AI Analyst Report?
Zim Laboratories Ltd. (ZIMLAB) AI Stock Analysis
Zim Laboratories Ltd.
(NSE:ZIMLAB)
The overall score is constrained by weak profitability and an extremely high valuation. The company's net income has fallen sharply, and the P/E ratio of 147.56 is a major red flag. Positive factors include a healthy balance sheet with low debt and moderately bullish technical momentum, with the stock trading above key moving averages. However, the negative free cash flow and declining margins are significant risks that outweigh these strengths.
Zim Laboratories Ltd. (ZIMLAB) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 7.98B
- Dividend Yield
- ―
- Average Volume (3M)
- 10.78K
- Price to Earnings (P/E)
- 280.8
- Beta (1Y)
- 0.81
- Revenue Growth
- 13.14%
- EPS Growth
- -60.77%
- Country
- India
- Employees
- 632
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Zim Laboratories Ltd. Business Overview & Revenue Model
Company Description
Established in 1984 and based in Nagpur, India, ZIM Laboratories Limited is a pharmaceutical company that develops, produces, and supplies both finished drug formulations and pre-formulation ingredients. Operating domestically and internationally, ZI...
Zim Laboratories Ltd. Financial Statement Overview
Summary
Financial performance is mixed. Revenue is stable but profitability has deteriorated sharply, with net margin falling to 1.6% and net income declining significantly. The balance sheet is healthy with low leverage, but return on equity is weak at 2.0%. Cash flow from operations is strong, but negative free cash flow due to high capex raises concerns about investment efficiency.
Income Statement
35NegativeBalance Sheet
70PositiveCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.14B | 3.69B | 3.74B | 3.68B | 3.99B | 3.31B |
| Gross Profit | 1.37B | 616.36M | 730.04M | 1.86B | 903.81M | 1.67B |
| EBITDA | 278.76M | 256.46M | 495.11M | 454.76M | 582.00M | 452.62M |
| Net Income | 20.71M | 58.38M | 121.65M | 172.46M | 244.34M | 145.50M |
Balance Sheet | ||||||
| Total Assets | 5.48B | 5.39B | 4.72B | 4.47B | 3.42B | 3.42B |
| Cash, Cash Equivalents and Short-Term Investments | 225.94M | 278.02M | 20.37M | 96.41M | 64.66M | 34.20M |
| Total Debt | 1.51B | 1.26B | 1.18B | 1.12B | 620.00M | 533.14M |
| Total Liabilities | 2.55B | 2.43B | 2.20B | 2.08B | 1.41B | 1.66B |
| Stockholders Equity | 2.92B | 2.96B | 2.52B | 2.39B | 2.00B | 1.76B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -75.72M | 3.57M | -576.45M | 15.00M | 339.81M |
| Operating Cash Flow | 0 | 368.15M | 411.55M | 162.78M | 381.68M | 492.06M |
| Investing Cash Flow | 0 | -565.23M | -399.27M | -730.13M | -362.04M | -145.71M |
| Financing Cash Flow | 0 | 410.81M | -91.05M | 595.34M | 5.46M | -329.70M |
Zim Laboratories Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZIMLAB, the sentiment is Positive. The current price of 148.15 is above the 20-day moving average (MA) of 136.51, above the 50-day MA of 137.63, and above the 200-day MA of 106.65, indicating a bullish trend. The MACD of 1.26 indicates Negative momentum. The RSI at 59.05 is Neutral, neither overbought nor oversold. The STOCH value of 52.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ZIMLAB.
Zim Laboratories Ltd. Peers Comparison
Overall Rating
IN:KILITCH65Neutral
IN:MEDICO63Neutral
IN:VALIANTLAB59Neutral
IN:ZIMLAB52.5Neutral
IN:ALBERTDAVD52Neutral
IN:BAFNAPH46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | INR 8.20B | 33.95 | ― | ― | 13.87% | -17.80% | |
| 63Neutral | INR 1.57B | 11.40 | ― | ― | 50.78% | 20.08% | |
| 59Neutral | INR 5.50B | 32.43 | ― | ― | 102.37% | 176.45% | |
| 53Neutral | INR 7.95B | 280.79 | ― | ― | 13.14% | -60.77% | |
| 52Neutral | INR 4.30B | 14.99 | ― | 0.66% | 19.69% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | INR 11.35B | 98.66 | ― | ― | 8.74% | 31.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ZIMLAB | Zim Laboratories Ltd. | 148.15 | 74.66 | 101.59% | |
| IN:ALBERTDAVD | Albert David Ltd | 753.60 | -29.76 | -3.80% | |
| IN:BAFNAPH | Bafna Pharmaceuticals Limited | 479.80 | 312.35 | 186.53% | |
| IN:KILITCH | Kilitch Drugs (India) Limited | 234.65 | 51.13 | 27.86% | |
| IN:MEDICO | Medico Remedies Ltd. | 18.86 | -32.23 | -63.08% | |
| IN:VALIANTLAB | Valiant Laboratories Ltd. | 101.20 | 28.20 | 38.63% |
Zim Laboratories Ltd. Corporate Events
Zim Laboratories’ CARE credit rating reaffirmed as outlook turns negative
Zim Laboratories Ltd. has disclosed that CARE Ratings has reaffirmed its credit ratings on the company’s bank facilities, signalling continued confidence from the rating agency in the firm’s credit profile. The long-term bank facilities of Rs 127.48...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026
